New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy ...

The other is an injection of antibodies — sold under the brand name Beyfortus, known by its scientific name nirsevimab — given to infants before their first RSV season, and a few high-risk ...

New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infantsParis, October 9, ...

Sanofi - Aventis Groupe said that the data featured at IDWeek from several national immunization programs will reinforce the proven ...

Thermo Fisher Scientific is responsible for helping to produce some of the hottest drugs on the market, including Novo ...

Paris, October 9, 2024. Sanofi advances its ambition to protect all infants from respiratory syncytial virus (RSV) disease with new Beyfortus (nirsevimab) data to be presented at the Infectious ...

Paris, October 9, 2024. Sanofi advances its ambition to protect all infants from respiratory syncytial virus (RSV) disease with new Beyfortus (nirsevimab) data to be presented at the Infectious ...